Dr. Kavita S. Sharma, M.D. Internal Medicine - Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 551 W Central Ave Ste 204, Delaware, OH 43015 Phone: 740-615-0400 Fax: 740-615-0401 |
Dr. Timothy L Timko, M.D. Internal Medicine - Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 7853 Pacer Dr Ste 3a, Delaware, OH 43015 Phone: 614-533-3470 Fax: 614-533-0069 |
Dr. Michael Anthony Bauml, M.D. Internal Medicine - Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 551 W Central Ave Ste 204, Delaware, OH 43015 Phone: 740-615-0400 Fax: 740-615-0401 |
Dr. Hyung Suk Kim, D.O. Internal Medicine - Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 7853 Pacer Dr Ste 3a, Delaware, OH 43015 Phone: 614-533-3470 Fax: 614-533-0069 |
Tejas A Mehta, MD Internal Medicine - Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 551 W Central Ave Ste 204, Delaware, OH 43015 Phone: 740-615-0400 Fax: 740-615-0401 |
News Archive
KPN, the leading telecommunications and ICT service provider in the Netherlands, and Dyzle BV, the global leader in measuring and analyzing business process data for the cold chain in real-time, have announced a collaboration to offer an integrated platform for monitoring, tracking, and providing real-time data analytics and visualization for the food and pharmaceutical industries.
Researchers exploring the notion that certain nutrients might protect against pancreatic cancer found that lean individuals who got most of these nutrients from food were protected against developing cancer.
It's just one little amino acid, but it makes all the difference in protecting the heart from the harmful effects of heart attack and cardiac failure. Researchers from the University of Michigan Medical School suggest this amino acid, called histidine, could be the key to a new therapy for cardiovascular disease
Shield Therapeutics, an independent specialty pharmaceutical company focused on the development of mineral-derived hospital pharmaceuticals, today announces that it has filed an investigational new drug application with the US Food and Drug Administration to initiate a Phase 3 pivotal study of ST10, its novel oral iron-replacement therapy, for the treatment of iron deficiency anaemia in pre-dialysis patients with chronic kidney disease.
The U.S. Department of Justice, on behalf of the U.S. Food and Drug Administration, has filed a complaint for permanent injunction against Rel's Foods Inc. (Rel's), of Oakland, Calif., seeking to stop the company from manufacturing, producing, and selling adulterated food products.
› Verified 1 days ago